Increasing evidence has shown that CCAR2 upregulation is associated with poor survival among tumor patients with breast carcinoma, gastric carcinoma, esophageal cancer, etc.[48], and CCAR2 may serve as a tumor diagnostic or therapeutic target[27]. This evidence concerns the gene CCAR2 and esophageal cancer.